The effect of the nitric oxide (NO) synthase inhibitor Nw-nitro-L-arginine methyl ester (L-NAME) on the response of cerebrocortical oxygen consumption (CMR02) and blood flow (CBF) to two levels of hyper capnia (PaC02 -60 mm Hg and Pac02 -90 mm Hg) was investigated in ketamine-anesthetized rats. CBF was cal culated using the Kety-Schmidt approach and CMR02 was calculated from the product of CBF and the arterio venous (superior sagittal sinus) difference for oxygen. L-NAME treatment did not have a significant effect on
The mechanism by which hypercapnia exerts its effect on cerebral blood flow is elusive. While part of the increase in cerebral blood flow is mediated through a local vascular reaction to hypercapnic ac idosis (Kontos et aI., 1977; Busija and Heistad, 1984) , a number of central neuronal and peripheral neurohormonal factors may also play a role (Shalit et aI., 1967; MacKenzie et aI., 1976; Hemmingsen et aI., 1979; Berntman et aI., 1979; Siesjo et aI., 1980; Reddy et aI., 1986; Bryan, 1990; Dora et aI., 1992) .
Nitric oxide (NO) is a recently discovered mes senger molecule that mediates a wide variety of physiological and pathological effects in the cardio vascular, endocrinological, peripheral nervous, and central nervous systems (for reviews see Moncada et aI., 1991; Ignarro, 1991; and Synder, 1992) . NO is either CMR02 or CBE under normocapnic conditions but inhibited the hypercapnic increase of CMR02 and the hy percapnic increase in CBF. These results suggest that NO plays a role in the response of CMR02 and CBF during hypercapnia and are consistent with the suggestion that at least part of the increase in CBF observed during hyper capnia is coupled to an increase in CMR02• Key Words: Cerebral oxygen consumption-Cerebral blood flow Hypercapnia-Nitric oxide-L-NAME.
produced from the terminal guanidine group of L-ar ginine by NO synthase (NOS) (Palmer et aI., 1988) . In the brain, NOS occurs in vascular endothelium (Moncada et aI., 1989; Nozaki et aI., 1992) , nerve fibers of the adventitial layer of cerebral arteries (N ozaki et aI. , 1992) , central neurons (Bredt et aI., 1990; Forstermann et aI., 1990) , and astrocytes (Murphy et aI., 1989) . NO is responsible for endo thelium-mediated relaxation of vascular smooth muscle (Moncada et aI., 1990) , and has been impli cated in neurogenic vasodilation of cerebral vessels Okamura, 1990, 1991) .
A number of groups have investigated the effects of NOS inhibitors on hypercapnic hyperemia. Three groups reported that inhibition of NOS re sulted in a severe diminution of the hypercapnic response of cerebral blood flow (Iadacola, 1992; Wang et aI., 1992; Pelligrino et aI., 1993) , but two groups reported no effect of NOS inhibitors on the hypercapnic response of cerebral blood flow (Ada chi et aI., 1992; Sokoloff et aI., 1992) . While these results suggest that NO may play an important role in hypercapnic hyperemia, details of this role are unclear.
Part of the role of NO in regulating cerebral blood flow in hypercapnia could be related to a possible role in regulating cerebral oxygen consumption in hypercapnia. In this study, we demonstrate that treatment of rats with the NOS inhibitor N w-nitro L-arginine methyl ester (L-NAME) (Moore et ai., 1990; Rees et aI., 1990) results in complete inhibi tion of the hypercapnic increase in cerebral oxygen consumption observed under hypercapnic condi tions. Inhibition of the hypercapnic increase in ce rebral oxygen consumption occurs in the same L-NAME concentration range that produces com plete inhibition of the hypercapnic increase in cere bral blood flow.
MATERIALS AND METHODS

General procedures
Experiments were carried out on male Fisher rats (Taconic Farms, Taconic, NY, U.S.A.) weighing 300-350 g. Animals had free access to water and commercial chow pellets. An initial dose (200 mg/kg) of ketamine hydro chloride (Ketaset, Bristol Laboratories, Syracuse, NY, U.S.A.) was injected i.p. and a maintenance dose (20-25% of the initial dose) was administered every 30-45 min. Polyethylene catheters were inserted in the right femoral artery (for measurement of arterial blood pres sure and heart rate and for withdrawal of arterial blood samples), the external jugular vein (for drug administra tion and isotope infusion), and the trachea. A 27-gauge needle was inserted into the superior sagittal sinus for cerebrocortical venous blood sampling (Dora et a!., 1992) , and stainless steel screws were fixed into the pa rietal bone for electroencephalographic (EEG) measure ment. Animals were immobilized with an i. v. injection (1 mg/kg) of pancuronium bromide (Pavulon, Organon, West Orange, NY, U.S.A.) and ventilated. Body temper ature, recorded with a rectal probe, was maintained at 37 ± 0.3°C.
Arterial blood pressure, heart rate, and EEG were monitored continuously (Gould Instruments, Oxnard, CA, U.S.A.). Arterial pH and blood gases were measured with a blood gas analyzer (Type 168, Ciba-Corning Diag nostics, Medfield, MA, U.S.A.) and total oxygen concen trations were measured with an oximeter (Lex-02-Con, Hospex, Chestnut Hill, MA, U.S.A.).
Cerebrocortical blood flow (CBF) was measured ac cording to the principles described by Kety and Schmidt (1948) . Tritiated water (in saline) was infused into the jugular vein while blood was withdrawn from the superior sagittal sinus and the aorta. At the end of the infusion, the animal was decapitated, and radioactivity determined in two (right and left) samples (-0.1 g) of the frontoparietal cortex and in arterial and venous blood samples. CBF was calculated from the ratio of counts (per unit weight) in the cortical brain samples to the product of the infusion time and the difference between counts (per unit volume) in arterial and superior sagittal sinus blood samples. Cere brocortical oxygen consumption (CMR02) was calculated from the product of CBF and the arteriovenous (superior sagittal sinus) difference for oxygen. Cerebrocortical vas cular resistance (CVR) was calculated as the ratio of mean arterial blood pressure (MABP) to CBF. Further details are given in Dora et a!. (1992) . Vol. 14, No.3, 1994 Experimental protocol Animals were allowed to stabilize for 20 min after the completion of surgery. At this point, L-NAME, o-NAME, or saline solutions in 0.2 ml of saline were injected i. v.; 25 min after this injection, arterial and ve nous (superior sagittal sinus) samples were taken for mea surement of total oxygen content and the CBF measured. Moderate (P aco2 -60 mm Hg) and severe (P aco2 -90 mm Hg) hypercapnia were induced by addition of CO2 to the gas mixture 5 min after administration of L-NAME, o-NAME, or control saline solutions. In some animals, L-arginine (600 mg/kg in 0.4 ml saline) was injected i. v. -3 min before injection of L-NAME. L-NAME, o-NAME, and L-arginine were obtained from Sigma Chemical Company (St. Louis, MO, U.S.A.).
Twelve groups of rats were used for these experiments: (a) saline-treated, normocapnic (n = 6); (b) 3 mg/kg L-NAME-treated, normocapnic (n = 8); (c) 30 mg/kg L-NAME-treated, normocapnic (n = 7); (d) saline treated, Paco2 = 60 mm Hg (n = 8); (e) 3 mg/kg L-NAME-treated, Paco2 = 60 mm Hg (n = 6); (f) 30 mg/kg L-NAME-treated, Pac02 = 60 mm Hg (n = 6); (g) saline-treated, Paco2 = 90 mm Hg (n = 6): (h) 3 mg/kg L-NAME-treated, Paco2 = 90 mm Hg (n = 6); (i) 30 mg/kg L-NAME-treated, Paco2 = 90 mm Hg, (n = 7); G) 3 mg/kg L-NAME-treated, 600 mg/kg L-arginine-treated, Paco2 = 90 mm Hg (n = 6); (k) 30 mg/kg L-NAME treated, 600 mg/kg L-arginine-treated, Pac02 = 90 mm Hg (n = 6); and (I) 30 mg/kg o-NAME-treated, Paco2 = 90 mm Hg (n = 6).
Data analysis
Results were analyzed using univariant analysis of vari ance (ANOV A) and are expressed as mean ± SD. The Games/Howell test (Games and Howell, 1976) , which specifically accounts for different SDs (Games et aI., \981), was used for subsequent "posthoc" comparisons.
Significance was set at the p < 0.05 level for each posthoc comparison.
Three sets of univariant posthoc comparisons (CBF, CMR02, and CVR) were performed. The first set com pared data for control and L-NAME-treated animals taken under moderate hypercapnic conditions (P aco2 -60 mm Hg) with the same data taken under normocapnic conditions. The second set compared data for control and L-NAME-treated animals taken under severe hypercap nic conditions (P aco2 -90 mm Hg) with the same data taken under normocapnic conditions. The third set com pared data for six groups of animals taken under severe hypercapnic conditions (PaC02 -90 mm Hg): control an imals, animals treated with L-NAME (3 mg/kg or 30 mg/ kg), animals treated with both L-arginine (600 mg/kg) and L-NAME (3 mg/kg or 30 mg/kg), and animals treated with o-NAME (30 mg/kg). Table 1 shows the physiological variables, ob tained immediately before the CBF measurements, for control animals and animals treated with L-NAME. In normocapnic animals, L-NAMR treat ment increased the MABP and decreased the heart rate compared to saline-treated animals. The in crease in MABP and decrease in heart rate were All values are means ± SD, L-NAME, Nw-nitro-L-arginine methyl ester; PaH, arterial pH; n, number of animals per group, " Significant differences (p < 0,05) from corresponding control (saline treated) values, b Significant differences (p < 0,05) from corresponding normocapnic values, complete within 5 min after addition of L-NAME and no further significant changes were observed during the experiment. 0-NAME treatment had no effect on MABP (see Fig. O . In the saline-treated animals,hypercapnia did not influence MABP or heart rate. In L-NAME-treated animals, hypercap nia decreased the elevation in MABP and further decreased the heart rate (see Table 1 and Fig. 1) . Table 2 shows the physiological variables for ani mals treated with both L-arginine and L-NAME and animals treated with o-NAME. For normocapnic animals, L-NAME treatment did not produce statistically significant changes in CBF or CMR02 compared to values found for the saline-treated controls (see Fig. 2 ). However, for hypercapnic animals, L-NAME treatment did pro duce a significant reduction in CBF and CMR02 compared to saline-treated controls (see below).
RESULTS
For saline-treated animals, moderate hypercap nia (P aco2 -60 mm Hg) increased CBF from 1.5 ± 0. 3 to 4. 1 ± 0. 9 ml g-I min-I and increased CMR02 from 5.8 ± 0.2 to 9. 6 ± 2. 3 j.Lmol g-I min-I (see Fig. 2 ). Under the same conditions, severe hy percapnia (P aco2 -90 mm Hg) increased CBF to 6. 0 ± 1.0 ml g-I min -1 and increased CMR02 to 7. 4 ± 0.5 j.Lmol g-I min -1.
For animals treated with 3 mg / kg L-NAME, mod erate hypercapnia (P aco2 -60 mm Hg) increased CBF from 1. 6 ± 0.6 to 3. 4 ± 1.1 ml g-I min -\ but did not cause a statistically significant change in CMR02 (8.7 ± 2. 6 j.Lmol g-I min -I for moderately hypercapnic animals compared to 6. 5 ± 0. 6 j.Lmol g -1 min -1 for normocapnic animals; see Fig. 2 ). Under the same conditions, severe hypercapnia (P aco2 -90 mm Hg) increased CBF to 2. 8 ± 0. 7 ml g-I min -I and decreased CMR02 to 5.1 ± 0. 8 j.Lmol g-I min -I .
For animals treated with 30 mg / kg L-NAME, moderate hypercapnia (P ac02 -60 mm Hg) did not cause a statistically significant change in CBF (1.5 ± 0. 2 ml g -1 min -1 for hypercapnic animals com pared to 1. 3 ± 0. 2 ml g -1 min -1 for normocapnic animals) and did not cause a statistically significant change in CMR02 (6. 5 ± 0. 6 j.Lmol g-I min -I for hypercapnic animals compared to 6. 1 ± 1. 0 j.Lmol g -1 min -1 for normocapnic animals; see Fig. 2 ). Under the same conditions, severe hypercapnia (P aco2 -90 mm Hg) did not cause a statistically significant change in CBF (1. 6 ± 0. 5 ml g-I min-I for hypercapnic animals compared to 1.3 ± 0. 2 ml g-I min -I for normocapnic animals), but decreased the CMR02 to 4. 5 ± 0. 8 j.Lmol g-I min -I . L-NAME treatment significantly increased the cortical vascular resistance in normocapnic and hy percapnic animals (see Fig. 3 ).
Treatment with 600 mg / kg L-arginine completely reversed the effects of 3 mg / kg L-NAME on CMR02 and CBF observed under severe hypercapnic con ditions (see Fig. 4 ). Treatment with 600 mg / kg L-ar ginine completely reversed the effects of 30 mg / kg All values are means ± SD. D-NAME. Nw-nitro-D-arginine methyl ester; PaH, ar terial pH; n, number of animals per group. a Significant differences (p < 0.05) from corresponding (saline treated) values (see Table 1 ). b Significant differences from corresponding L-NAME-treated groups.
L-NAME on the CMR02 observed under severe hy percapnic conditions, but only partly reversed the effects of 30 mg / kg L-NAME on the CBF observed under the same conditions (see Fig. 4 ). D-NAME (30 mg / kg) treatment did not significantly alter the CBF or CMR02 observed under severe hypercap nic conditions (see Fig. 4 ). 
DISCUSSION
The major result of this study is that inhibition of the hypercapnic increase in CBF by treatment with the NOS inhibitor L-NAME is accompanied by an inhibition of the hypercapnic increase in CMR02• For example, treatment with 30 mg / kg L-NAME completely abolished the increases in CBF and CMR02 observed under moderate (P aco2 -60 mm Hg) hypercapnic conditions (see Fig. 2) .
Increases in CMR02 observed for ketamine anesthetized control (saline-treated) rats under moderate (P aco2 -60 mm Hg) and severe (P aco2 -90 mm Hg) hypercapnia are similar to the increases in CMR02 observed with nitrous oxide (NO) anesthetized rats under hypercapnic conditions (PaC02 -80 mm Hg) (Hemmingsen et aI., 1979; Berntman et aI., 1979) . A p ossible mechanism for the observed cortical stimulation during hypercap nia could be an indirect effect due to activation of t h e brain stem by CO2 (Woodbury and Karler, 1960; Sh alit et aI., 1967; Siesjo, 1980; Reddy et aI., 1987) . Whatever the mechanism, the observation that L-NAME treatment inhibited the hypercapnic in crease in CMR02 suggests that the observed acti vation of cortical metabolic activity by hypercapnia is mediated through NO pathways.
Treatment with 30 mg / kg L-NAME not only abol ished the increase in CMR02 observed during se vere (P aco2 -90 mm Hg) hypercapnia but also re sulted in a CMR02 value that was significantly be low the corresponding normocapnic value (see Fig.  2 ). This observation cannot be explained simply as the reversal of a hypercapnic cortical stimulation. Nor can it be explained as a direct effect of L-NAME on the resting CMR02 since L-NAME does not affect the normocapnic CMR02 (see Fig.  2 ). One explanation for this observation could be that the extreme acidosis observed with severe hy percapnia could directly inhibit cerebral cortical glucose metabolism (Miller et aI. , 1975; Borgstrom et aI., 1976; Siesjo, 1980) . This explanation is con sistent with the observation that the increase in CMR02 for control (saline-treated) animals is sub stantially larger under moderate hypercapnic con ditions (65%) than under severe hypercapnic condi tions (29%). It is also consistent with the observa tion that the decrease in CMR02 caused by treatment with 30 mg / kg L-NAME is similar (�3 f.Lmol g -1 min -1 ) in both moderate and severe hy percapnia.
While the data shown in Fig. 2 suggest that part of the increase in CBF in hypercapnia is related to an NO-mediated increase in CMR02, it does not rule out contributions to the hypercapnic increase in CBF from other mechanisms. However, the obser vation that L-NAME treatment completely inhib ited the hypercapnic response of CBF (see Fig. 2 ) implies that all of the mechanisms that contribute to the hypercapnic increase in CBF must involve NO sensitive pathways. Another mechanism for the hy percapnic increase in CBF could be a "direct" ef fect of CO2 on cerebral arteries due to extracellular acidosis (Kontos et aI., 1977; Busija and Heistad, 1984) . This "direct" effect of extracellar acidosis could be mediated by vascular endothelium or peri vascular nerves that contain NOS (Bredt et aI., 1990; Nozaki et aI., 1992) .
The observation that L-NAME treatment did not affect the normocapnic CBF does not rule out a direct effect of L-NAME under these conditions. For example, it is possible that L-NAME treatment increased resistance in large extracranial vessels, but that pial vessel dilation compensated for this effect.
Ketamine inhibits the N-methyl-D-aspartate (NMDA) receptor (Lodge and Johnson, 1990) . If the hypercapnic increases in CBF and CMR02 ob served in the present study involved NMDA recep tors (Synder, 1992) , they should be inhibited by ke-tamine. The hypercapnic increases in CBF and CMR02 observed under ketamine anesthesia and the large effects of L-NAME on these increases sug gest that at least some of the NO-sensitive path ways responsible for these effects do not involve NMDA receptors.
L-NAME has been shown to be an inhibitor of muscarinic receptors (Buxton et aI., 1993) . The an tagonism of NO synthesis and the antagonism of muscarinic receptors can be distinguished using L-arginine (Moncada et aI., 199 1) . The observation that treatment with 600 mg / kg L-arginine reversed the effects of 3 mg / kg L-NAME on the CBF and CMR02 under severe hypercapnic conditions sug gests that all of the effects of this dose of L-NAME are mediated through an inhibition of the NOS pathway. The observation that treatment with 600 mg / kg L-arginine reversed the effects of 30 mg / kg L-NAME on the CMR02 under severe hypercapnic conditions but only partly reversed the effects on control (saline treated) animals, animals treated with L-NAME, animals treated with both L-NAME and L-arginine, and animals treated with D-NAME. Values are means ± SO.
Significant differences (p < 0.05) from the control (saline treated) value are designated by #. For animals treated with both L-NAME and L-arginine, significant differences from the corresponding values for animals treated with L-NAME alone are designated by t.
the CBF observed under these conditions (see Fig.  4 ) suggests that part of the effects of the higher dose of L-NAME on the hypercapnic CBF could be due to other mechanisms. An alternative explanation is that the dose of L-arginine used for these experi ments was not sufficient to completely reverse the effects of the high dose of L-NAME. The conclusion from the L-arginine studies that most of the effects of L-NAME are due to inhibition of the NO synthesis pathway is consistent with the observation that treatment of the animals with 30 mg / kg o-NAME did not significantly affect the CBF or the CMR02 under severe hypercapnic condi tions.
Published results on the effects of NOS inhibitors on normocapnic and hypercapnic CBF are some what contradictory. Some groups reported that NOS inhibitors decreased normocapnic CBF (Tanaka et aI., 1991; Kozniewska et aI., 1992; Northington et aI., 1992; Prado et aI., 1992; Sokoloff et aI., 1992; Wang et aI., 1992; Pelligrino et aI., 1993) , while others reported no significant effect on normocapnic cortical CBF (Adachi et aI., 1992; Iadecola, 1992; Kovach et aI. , 1992; Yamamota et aI., 1992) . Likewise, some groups reported that NOS inhibitors decreased the hypercapnic response of CBF (Iadecola; 1992; Wang et aI., 1992; Pelli grino et aI., 1993) , while other groups reported no significant effect (Adachi et aI. , 1992; Sokoloff et aI., 1992) . The different results could be due to dif ferent experimental conditions or to the use of dif ferent experimental techniques, which may mea sure blood flow in different regions of the brain.
The observation that L-NAME does not inhibit CMR02 under normocapnic conditions (see Fig. 2 ) is consistent with previous observations that Nomonomethyl-L-arginine (L-NMMA) does not inhibit CMR02 (Kozniewska et aI., 1992) and that N", nitro-L-arginine (L-NA) does not inhibit CMRglc (Ia decola and Xu, 1993) under normocapnic condi tions.
Previous studies have shown that i. v. administra tion of L-NAME to rats led to marked blood pres sure elevation accompanied by bradycardia (Gar diner et aI., 1990a (Gar diner et aI., , 1990b Wang and Pang, 1990; Widdop et aI., 1992; Togashi et aI., 1992) . The present results confirm these findings and show that in L-NAME-treated animals, hypercapnia attenu ated the elevated blood pressure and further de pressed the decreased heart rate. These changes in the systemic hemodynamic variables could have in fluenced the increase in CBF observed during hy percapnia.
In summary, our results demonstrate that treat ment with the NOS inhibitor L-NAME completely J Cereb Blood Flow Me/ab, Vol. 14, No.3, 1994 inhibits the hypercapnic increase in CMR02 in the same concentration range that gives complete inhi bition of the hypercapnic response of CBF. These results suggest that part of the hypercapnic increase in CBF could be coupled to the hypercapnic in crease in CMR02•
